<DOC>
	<DOCNO>NCT00866320</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sorafenib work treat patient metastatic kidney cancer respond sunitinib bevacizumab .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Metastatic Kidney Cancer That Has Not Responded Sunitinib Bevacizumab</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine tumor burden reduction rate patient sunitinib malate- bevacizumab-refractory , metastatic clear cell renal cell carcinoma treat sorafenib tosylate . Secondary - To determine safety sorafenib tosylate patient . - To record duration tumor reduction , time disease progression , overall survival patient treat sorafenib tosylate . OUTLINE : Patients receive oral sorafenib tosylate twice daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma component clear cell histology Metastatic disease Disease progression , define RECIST criterion , prior treatment sunitinib malate bevacizumab Patients must receive ≥ 1 course ( 4 week ) sunitinib malate ≥ 2 dos bevacizumab AND RECISTdefined objective progression within 4 month complete treatment sunitinib malate bevacizumab Measurable disease RECIST criterion CNS metastasis allow provided patient undergone prior surgery and/or radiotherapy AND evidence CNS disease progression CT scan MRI ≥ 2 week treatment CNS metastases PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 Karnofsky PS 70100 % WBC ≥ 3,000/μL Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 75,000/μL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST/ALT ≤ 2.5 time ULN Creatinine ≤ 2.0 time ULN Negative pregnancy test No significant cardiovascular disease , include follow : Congestive heart failure ( New York Heart Association class IIIIV heart disease ) Active angina pectoris require nitrate therapy Uncontrolled dysrhythmias Cardiovascular event within past 6 month ( e.g. , transient ischemic attack/cerebrovascular accident , myocardial infarction , vascular surgery ) PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 2 week since prior systemic therapy , radiotherapy , major surgery recover No prior sorafenib tosylate No concurrent investigational agent No concurrent anticancer therapy No concurrent prophylactic growth factor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>